AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02660632 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Thoracic epidural analgesia (TEA)
Description: Epidural catheter will be inserted at T9-T11. Then, epidural analgesia will be activated with administering bolus of 10 mls 0.25% bupivacaine in conjunction with100 mcg fentanyl to establish a block. This will be followed by an infusion of 0.125% bupivacaine in conjunction with 2 mcg/ ml fentanyl at a rate of 10 mls /hour and then titrated to effect for up to 48 hour postoperative
Study NCT02660632 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rectus sheath catheter block
Description: Following insertion of bilateral rectus sheath catheters, 20 ml of 0.25% bupivacaine will be injected through each one. Then continuous infusion pumps will be connected to the catheters and set to deliver boluses of 20 mL of 0.25% bupivacaine, with a 4-hour lockout for up to 48 h postoperatively.
Study NCT03691116 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Health Profile
Description: Screening, health check-up and automatic feedback in the areas tobacco, alcohol, exercise and diet, used on a National digital platform (Stöd och Behandlingsplattformen, SoB)
Study NCT03691116 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Ordinary psychological assessment and counseling.
Study NCT03691116 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Ordinary psychological assessment and counseling.
Study NCT03294512 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAWDS data entry on app
Description: Utilize the smartphone app to enter their MAWDS (Medication, Activity, Weight, Diet, Symptoms) data
Study NCT03031522 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-IRS
Description: According to experiment, 18F-IRS was non-toxic and stable in serum.
Study NCT04830475 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non invasive ventilation (NIV)
Description: Patients allocated in NIV Group fulfilled a 120-minute cycle of PSV + PEEP with full-face mask. Ventilation was performed with a Draeger Ventilator with the following basic settings: DeltaPInsp 10 mmHg + PEEP 5 mmHg + Fio2 60%.
Study NCT04830475 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Venturi Mask
Description: Patients were offered VenturiMask with Fio2 60% at 15 l / m.
Study NCT02815462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FAMFACESG
Description: - PNs will receive the FAM-FACE-SG FA risk scores for frequent admitters admitted to their ward.
Study NCT02815462 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: - Usual hospital Care
Study NCT02815462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FAMFACESG
Description: - PNs will be instructed to prioritize intervention of frequent admitters for intervention based on the FA risk score.
Study NCT02815462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FAMFACESG
Description: * For high and moderate risk patients who do not require transitional home care (THC), PN will do the case management and follow up.~* For high and moderate risk patients \& have complex nursing and / or high functional needs, PNs will refer these patients for THC.~* For mild risk patients, PNs will refer them to care coordinator.
Study NCT02815462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FAMFACESG
Description: - For low risk patients, PNs will continue usual hospital care.
Study NCT01417572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: to evaluate the effect of lidocaine on oculocardiac reflex during the surgery
Study NCT02668224 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrasens
Description: Transcutaneous vibrations are used. This device allows vibrations from 25 to 150 Hz with an amplitude of 1 mm. In our study the frequency used is 50 Hz.
Study NCT02668224 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual activities
Description: The patients will perform their usual activities, to allow the comparison with a vibration programme. They will not have a specific training.
Study NCT00251862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based decision aid plus personalized risk assessment
Description: Patients review a computer-based decision aid that discuss the pros and cons of of 5 recommended CRC screening options and provides personalized 10-year estimates of CRC risk prior to meeting with their provider to discuss CRC screening.
Study NCT03087851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: Intravenous infusion of 5 mg zoledronic acid
Study NCT00251862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based decision aid alone
Description: Patients review a computer-based decision aid that discuss the pros and cons of the 5 recommended CRC screening options prior to meeting with their provider to discuss CRC screening.
Study NCT00251862 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Generic website
Description: Patients review a generic website that discuss ways to reduce overall cancer risk.
Study NCT01587534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norzyme
Description: Patients will be randomized to receive either pancreatic enzyme replacement therapy or placebo. Patients will use two capsules three times daily during main meals and one capsule three times daily during in between snacks. The pancreatic enzyme preparation under investigation is Norzyme ® 6 - 9 tablets per day.
Study NCT04371471 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: STC-19 score
Description: Score calculated by an algorithm using a vital sign (systolic blood pressure) and biomarkers (complete blood count with differential)
Study NCT05669287 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT Perfusion
Description: CT Perfusion
Study NCT02039297 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation
Description: Computer aided checklist and rounding tool implemented in the Intensive care unit environment
Study NCT02832219 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Molecular hydrogen
Study NCT02832219 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04178096 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Quality Improvement Intervention
Description: The investigators will assess the effectiveness of empirically determined implementation strategies that are associated with increasing cirrhosis evidence based practices and thus improving outcomes of Veterans with cirrhosis by introducing a bundle of these strategies to four new 'low-performing' hospitals every six months during and eighteen month period in this stepped wedge cluster randomized trial.
Study NCT01448447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mammosite ML
Description: 34 Gy / 10 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 5 consecutive working days
Study NCT01448447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mammosite ML
Description: 5-10.2 Gy / 2-3 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 1-2 days Followed by whole breast radiation (25-28 daily tx)
Study NCT01812421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertension Health Education Protocol (HHEP)
Study NCT03588390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1323495
Description: Low strength tablet
Study NCT02413164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A multimodal physiotherapy programme
Description: Intervention: individualised Multimodal Physiotherapy Programme of therapeutic exercises with education healthy-style-of-life based.~Groupal sessions two times per week during 12 weeks. Each session 60 minutes: 10 minutes of warm up, 20 minutes of strength and muscular endurance, 20 minuts of aerobic training, 10 minutes of cold-down.~Intensity aerobic training: The training heart rate will be calculated according to recommendations of the American College of Sport Medicine (ACSM), it must oscillate between 55/65% and 90% of the HRmax. Initial four weeks: moderate intensity (55-69% HRmax); Following weeks according to each response, to higher level of training (70-89% HRmax). Strength training: individualised working with the principal muscular groups. 3 sessions using a weight which can repeat the exercise 10-15 times, increasing to a weight at which they can repeat the exercise 8-12 times.
Study NCT02159742 — intervention group
Intervention type: OTHER
Intervention: Data Collection
Study NCT01972958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: comprehensive care
Description: comprehensice assessment,physical activity training, community resources referral, health education.
Study NCT00825266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bosentan
Description: Bosentan 62.5 mg BID for 4 weeks, then 125mg BID for duration of study.
Study NCT00825266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 15 mg a day for 4 weeks then Pioglitazone 30 mg a day for the duration fo the study.
Study NCT01831622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritalin
Description: On one of the two test-dates the patient participant is administered methylphenidate, in the dose prescribed by the patients doctor.
Study NCT01502787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol succinate
Description: The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
Study NCT01831622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: On one of the test-dates the patient participants are administered a sugar pill, matching their prescribes medical dose.
Study NCT02215122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGR001
Description: Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
Study NCT02215122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advair® Diskus®
Description: Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
Study NCT03588390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1323495
Description: Middle strength tablet
Study NCT03588390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1323495
Description: High strength tablet
Study NCT03588390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to low strength tablet
Study NCT03588390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to middle strength tablet
Study NCT02215122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide™ Accuhaler™
Description: Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
Study NCT04364373 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left colon resection
Description: This procedure is performed for tumours in splenic flexure and proximal and descending colon.~Left colic artery is divided at its origin. Sigmoid arteries and superior rectal arteries are preserved. Inferior mesenteric vein is divided at the lower border of the pancreas. The colon is divided about 10 cm proximal and distal to the tumour. Mesocolic fascia is preserved and the length of the vessel trunk of the mesocolon corresponds to the level of lymph node dissection. After removal of the resected colonic segment a handsewn or stapler end-to-end or side-to-side colonic anastomosis is performed.
Study NCT01502787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
Study NCT04364373 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left colon resection
Description: This procedure is performed for tumours in splenic flexure and proximal and descending colon.~Left colic artery is divided at its origin. Sigmoid arteries and superior rectal arteries are preserved. Inferior mesenteric vein is divided at the lower border of the pancreas. The colon is divided about 10 cm proximal and distal to the tumour. Mesocolic fascia is preserved and the length of the vessel trunk of the mesocolon corresponds to the level of lymph node dissection. After removal of the resected colonic segment a handsewn or stapler end-to-end or side-to-side colonic anastomosis is performed.
Study NCT04364373 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sigmoid colon resection
Description: This procedure is performed for tumours in sigmoid colon. Corresponding sigmoid arteries are divided at their origin. Left colic artery and superior rectal artery are preserved. Inferior mesenteric vein is divide close to the left colic artery. Proximal and distal margin compose 10 cm from the tumour. Mesocolic fascia is preserved and the length of the vessel trunk of the mesocolon corresponds to the level of lymph nodes dissection. After removal of the resected colonic segment a handsewn end-to-end or side-to-side or stapler colonic anastomosis is performed.
Study NCT04364373 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sigmoid colon resection
Description: This procedure is performed for tumours in sigmoid colon. Corresponding sigmoid arteries are divided at their origin. Left colic artery and superior rectal artery are preserved. Inferior mesenteric vein is divide close to the left colic artery. Proximal and distal margin compose 10 cm from the tumour. Mesocolic fascia is preserved and the length of the vessel trunk of the mesocolon corresponds to the level of lymph nodes dissection. After removal of the resected colonic segment a handsewn end-to-end or side-to-side or stapler colonic anastomosis is performed.
Study NCT04364373 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal sigmoid colon resection or anterior resection
Description: This procedure is performed for tumours in distal sigmoid colon or rectosigmoid junction. Superior rectal artery is divided below the origin of left colic artery. Left colic artery is preserved. Inferior mesenteric vein is divide close to the left colic artery. The colon is divided about 10 cm proximal and 5 cm distal to the tumour. Mesocolic fascia is preserved and the length of the vessel trunk of the mesocolon corresponds to the level of lymph node dissection. After removal of the resected colonic segment handsewn or stapler colo-rectal anastomosis is performed.
Study NCT04364373 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal sigmoid colon resection or anterior resection
Description: This procedure is performed for tumours in distal sigmoid colon or rectosigmoid junction. Superior rectal artery is divided below the origin of left colic artery. Left colic artery is preserved. Inferior mesenteric vein is divide close to the left colic artery. The colon is divided about 10 cm proximal and 5 cm distal to the tumour. Mesocolic fascia is preserved and the length of the vessel trunk of the mesocolon corresponds to the level of lymph node dissection. After removal of the resected colonic segment handsewn or stapler colo-rectal anastomosis is performed.
Study NCT02669784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Contrast (Omnipaque) 40mL
Description: The patient will be administered a low dose, 40mL of intravenous contrast (Omnipaque) at a rate of 5mL/sec based on the area of the body being scanned (chest versus chest and abdomen versus chest, abdomen and pelvis). This will be compared to the patient's prior examination performed with 100mL of intravenous contrast at a rate of 4mL/sec.
Study NCT02669784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Contrast (Omnipaque) 50 mL
Description: The patient will be administered a low dose, 50mL of intravenous contrast (Omnipaque) at a rate of 5mL/sec based on the area of the body being scanned (chest versus chest and abdomen versus chest, abdomen and pelvis). This will be compared to the patient's prior examination performed with 100mL of intravenous contrast at a rate of 4mL/sec.
Study NCT03083587 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal lifestyle
Description: Normal lifestyle
Study NCT03083587 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Mild exercise 3 min every half hour
Study NCT03083587 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: muscle and fat biopsy
Description: Biopsy under local anesthesia
Study NCT03083587 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: muscle and fat biopsy
Description: Biopsy under local anesthesia
Study NCT03083587 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring
Description: Glucose concentrations during the study period
Study NCT03083587 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous glucose monitoring
Description: Glucose concentrations during the study period
Study NCT03083587 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activity monitoring (ActivePal)
Description: Objective measurements of standing and sitting time
Study NCT03083587 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activity monitoring (ActivePal)
Description: Objective measurements of standing and sitting time
Study NCT04791982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational sessions
Description: Firstly, the literature was scanned and a education booklet prepared after the opinions of 5 academic nurses, who are experts in the field of oncology, was used. The booklet was included colorectal cancer treatment, symptoms that may develop due to chemotherapy and information on their control, psychosocial support of caregiving family members. Interviews and educational sessions with family members who agreed to participate in the study were held in one-on-one and face-to-face meeting room. These interviews lasted approximately 45 to 60 minutes for each family member. In the interviews, a educational booklet containing information on nutrition, exercise, symptom management, physical aspects of care and disease-specific care was used to present information to caregivers. All of educational sessions were performed by the single researcher.
Study NCT00895401 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nepro with Carb Steady
Description: Nepro with Carb Steady is a commercially available renal specific oral nutritional supplement designed to meet the nutrient needs of dialysis patients. The supplement is 8 oz and provides 425 kcal and 19 grams of protein.
Study NCT00895401 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care for malnourished maintenance hemodialysis patients
Study NCT04014764 — intervention group
Intervention type: OTHER
Intervention: This is a non-interventional study
Description: N/A. This is a non-interventional study. Following consent, the subject will have biospecimen samples taken during routine standard of care procedures, and provided to Sponsor for analysis. Optional research blood draws may occur at treating physician's discretion to obtain additional tissue samples.
Study NCT04216810 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: muscle strengthening exercises
Description: segmental stabilization exercises
Study NCT04216810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: muscle strengthening exercises and dry cupping
Description: segmental stabilization exercises and dry cupping
Study NCT04447170 — intervention group
Intervention type: PROCEDURE
Intervention: Simple repair or Graham technique
Description: Simple suture with or without omental protective patch
Study NCT02747238 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: The ultrasound imaging of the lumbar spine in different scanning planes facilitates the identification of the landmarks necessary for appropriate epidural space location in pregnant patients. There are two acoustic windows that are effective for lumbar spine sonographic assessment: one seen on the transverse approach, and the other seen on the longitudinal paramedian approach. The ultrasound single-screen method using the transverse approach of the lumbar spine provides reliable information regarding the landmarks required for labor epidurals. The correct interspace and midline position are identified for correct placement of the CSE analgesia.
Study NCT02747238 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No ultrasound
Description: Palpation of anatomical landmarks is used for placement of labor analgesia
Study NCT02747238 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural infusion
Description: An epidural infusion will be started in both groups, regarding of the technique used for placement, and the same solution of Bupivacaine 0.0625% with 2mcg fentanyl/cc will be used in both groups
Study NCT02471651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone intravitreal implant (0.7 mg)
Description: Subjects with persistent DME who are randomized to this arm may get up to 3 treatments with the implant (0.7 mg dexamethasone).